Literature DB >> 7635874

Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma.

S Vesalainen1, P Lipponen.   

Abstract

The expression of Rb protein was analysed by immunocytochemical methods in 118 patients with T12M0 prostatic adenocarcinoma who were followed-up for more than 12 years. Rb protein was expressed in 117/118 (99%) tumours. The fraction of positive nuclei was (mean +/- SD, 92 +/- 19%) and only one tumour was completely negative for Rb protein. Abnormal expression of the Rb protein (in fewer than 90% of cells) was independent of the T category while there was a significant relationship between DNA ploidy (P = 0.0138), S-phase fraction (P = 0.0042) and expression of the Rb protein. Abnormal expression of the Rb protein had no prognostic value while T category (P = 0.0017), Gleason score (P = 0.0097), DNA ploidy (P = 0.0034), S-phase fraction (P = 0.0179) and mitotic index (P = 0.0001) were significant prognostic factors. In multivariate analysis the only independent predictor was the mitotic index [Risk ratio (RR) (95%CI) = 7.4(2.4-22.5), P = 0.004]. The results show that Rb protein immunohistochemistry has hardly any prognostic significance in prostatic adenocarcinoma whereas direct measurement of cell proliferative activity contains significant prognostic information.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635874     DOI: 10.1007/bf01212951

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

Review 1.  Molecular genetics of the retinoblastoma suppressor gene.

Authors:  R Bookstein; W H Lee
Journal:  Crit Rev Oncog       Date:  1991

2.  Is delayed treatment justified in carcinoma of the prostate?

Authors:  M C Parker; A Cook; P R Riddle; I Fryatt; J O'Sullivan; R J Shearer
Journal:  Br J Urol       Date:  1985-12

3.  Changes in growth and tumorigenicity following reconstitution of retinoblastoma gene function in various human cancer cell types by microcell transfer of chromosome 13.

Authors:  A Banerjee; H J Xu; S X Hu; D Araujo; R Takahashi; E J Stanbridge; W F Benedict
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

4.  Prognostic factors in prostatic adenocarcinoma assessed by means of quantitative histology.

Authors:  M Eskelinen; P Lipponen; R Majapuro; K Syrjänen
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

5.  Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma.

Authors:  S L Vesalainen; P K Lipponen; M T Talja; E M Alhava; K J Syrjänen
Journal:  Int J Cancer       Date:  1994-07-15       Impact factor: 7.396

6.  Epidermal growth factor and prostatic carcinoma: an immunohistochemical study.

Authors:  J E Fowler; J L Lau; L Ghosh; S E Mills; A Mounzer
Journal:  J Urol       Date:  1988-04       Impact factor: 7.450

7.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.

Authors:  J W Harbour; S L Lai; J Whang-Peng; A F Gazdar; J D Minna; F J Kaye
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

8.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.

Authors:  S H Friend; R Bernards; S Rogelj; R A Weinberg; J M Rapaport; D M Albert; T P Dryja
Journal:  Nature       Date:  1986 Oct 16-22       Impact factor: 49.962

9.  Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy.

Authors:  T Visakorpi; O P Kallioniemi; I Y Paronen; J J Isola; A I Heikkinen; T A Koivula
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

10.  Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.

Authors:  S Vesalainen; S Nordling; P Lipponen; M Talja; K Syrjänen
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.